Management appointments at Novasep
pharmafile | June 15, 2010 | Appointment | Manufacturing and Production | Novasep, appointment, manufacturing and production
Pharma manufacturing company Novasep has appointed Stephen Stefano to head up its US business and Patrick Glasser to lead its Novasep Synthesis division.
Stephen Stefano becomes president and chief executive of Novasep’s North American business and Patrick Glaser has been made president and chief executive of the Novasep Synthesis division, a new position created as a result of its ongoing global integration.
Before joining Novasep, Stefano was senior vice president at GlaxoSmithKline Pharmaceuticals in charge of business development for North America and new product planning.
His career spanned 29 years from 1981-2010 at Glaxo, GlaxoWellcome and GlaxoSmithKline, where he directed the sales of most business segments including primary care, specialty, hospital, and managed healthcare. He had full P&L responsibility for several multi-billion dollar divisions.
Meanwhile, Glaser has held senior management, strategic marketing and strategic business development positions successively at Knoll Pharmaceuticals (1986-1998), BASF Corporation (1998-2005) and Dr Reddy’s Laboratories (2005-2009), where he was vice president of its active pharmaceutical ingredient business, and recently in charge of a strategic contract manufacturing acquisition and integration.
As part of their new appointments Stefano and Glaser will also join the Novasep Group’s executive management committee.
The company has six FDA inspected manufacturing plants in France, Germany and the Bahamas, two biopharmaceutical production sites in Belgium, R&D and equipment manufacturing facilities in the US, China and France, and an office in Japan.
Related Content
Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
